Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Lilly, Boehringer Ingelheim announce availability of My Well Planner for adults with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announce the availability of a new online program offering customized educational content to help adults with type 2 diabetes make simple lifestyle changes to improve their health.

14 Sep 2012

Nature examines efforts to combat antibiotic resistance in India

Nature examines efforts to combat antibiotic resistance in India, writing, "Antibiotic resistance is a problem worldwide, but is particularly worrying in India, where hospital standards are inconsistent and antibiotics are readily available over the counter at pharmacies."

13 Sep 2012

Case Western Reserve researcher discovers new antivirulence drugs against MRSA and strep

Menachem Shoham, PhD, associate professor of biochemistry at Case Western Reserve University School of Medicine, has discovered novel antivirulence drugs that, without killing the bacteria, render Methicillin Resistant Staphylococcus Aureus (MRSA) and Streptococcus pyogenes, commonly referred to as strep, harmless by preventing the production of toxins that cause disease.

13 Sep 2012

Positive data from Tetraphase Pharmaceuticals’ eravacycline Phase 2 trial on cIAI

Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing novel antibiotics effective against antibiotic-resistant bacteria, presented new, positive Phase 2 clinical data on its lead drug candidate, eravacycline (TP-434), on September 11, 2012, at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

13 Sep 2012

Novel method could help advance fight against persistent 'HIV latency'

Scientists at the Gladstone Institutes have gotten us one step closer to understanding and overcoming one of the least-understood mechanisms of HIV infection-by devising a method to precisely track the life cycle of individual cells infected with HIV, the virus that causes AIDS.

12 Sep 2012

New model reveals how immune system functions under conditions of neutropenia

Cancer chemotherapy can be a life-saver, but it is fraught with severe side effects, among them an increased risk of infection. Until now, the major criterion for assessing this risk has been the blood cell count: if the number of white blood cells falls below a critical threshold, the risk of infection is thought to be high.

12 Sep 2012

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Santarus, Inc. today announced that its Phase III clinical study to evaluate the safety and efficacy of the investigational drug, rifamycin SV MMX, met the primary endpoint of reducing time to last unformed stool (TLUS) in patients with travelers' diarrhea.

12 Sep 2012

Durata Therapeutics completes dalbavancin Phase 3 trials on ABSSSI

Durata Therapeutics today announced results from its QT study of the company's lead product candidate, dalbavancin. Dalbavancin is currently under investigation in two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

11 Sep 2012

Arsanis to develop monoclonal antibody therapeutics against nosocomial infections

Arsanis Biosciences GmbH, an early stage biotechnology company developing anti-infective human monoclonal antibodies, today announced the award of two major grants for the development of monoclonal antibody therapeutics against nosocomial infections.

11 Sep 2012

Strep throat should be treated with penicillin or amoxicillin: IDSA guidelines

Although people often say they have "strep" throat, most sore throats actually are caused by a virus, not streptococcus bacteria, and shouldn't be treated with antibiotics, suggest guidelines published by the Infectious Diseases Society of America (IDSA). Antibiotics are ineffective against viruses.

11 Sep 2012

Methodist Hospital develops new technology to rapidly detect drug-resistant TB

Technology developed by scientists at The Methodist Hospital Research Institute could halve the time it takes to diagnose tuberculosis infection, and also tell doctors in a day or two whether the bacteria are drug resistant -- a process that currently takes weeks. Initial tests of the device were recently described in Scientific Reports, a Nature online journal.

11 Sep 2012

Recent data from Silence Therapeutics’ Atu111 pre-clinical study on acute lung injury

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company is pleased to announce that recent data in pre-clinical models demonstrated the efficacy of Atu111 in acute lung injury.

10 Sep 2012

Scientists characterize the lung squamous cell carcinoma genome

In the September 9, 2012 early online edition of Nature, scientists with The Cancer Genome Atlas (TCGA) report that they have characterized the lung squamous cell carcinoma genome.

10 Sep 2012

Antibiotic treatment more effective than placebo in patients with mild-to-moderate COPD

Antibiotic treatment with amoxicillin/clavulanate improves moderate exacerbations in patients with mild-to-moderate chronic obstructive pulmonary disease (COPD) and significantly prolongs the time between exacerbations, according to a new study from researchers in Spain.

10 Sep 2012

Research roundup: Reducing risk in shared savings programs

The Design And Application Of Shared Savings Programs: Lessons From Early Adopters --"Shared savings programs reward providers for holding spending below specific targets, thus introducing a level of financial accountability not present in strictly volume-based payment models, such as fee-for-service," researchers write.

7 Sep 2012

Enrollment complete in DOUBle Phase 3 clinical trial of AzaSite Plus and DexaSite for blepharitis

InSite Vision Incorporated today announced that patient enrollment has been completed in the DOUBle Phase 3 clinical trial of AzaSite Plus (ISV-502) and DexaSite (ISV-305) for the treatment of blepharitis.

7 Sep 2012

Durata completes target enrollment in dalbavancin Phase 3 trials for abSSSI

Durata Therapeutics today announced that it has completed its target enrollment for DISCOVER 1 ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response"), one of two ongoing, global, Phase 3 clinical trials of Durata's lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and skin structure infections (abSSSI).

7 Sep 2012

Antibiotic News and Research

Further Reading

Lilly, Boehringer Ingelheim announce availability of My Well Planner for adults with type 2 diabetes

Nature examines efforts to combat antibiotic resistance in India

Case Western Reserve researcher discovers new antivirulence drugs against MRSA and strep

Positive data from Tetraphase Pharmaceuticals’ eravacycline Phase 2 trial on cIAI

Novel method could help advance fight against persistent 'HIV latency'

New model reveals how immune system functions under conditions of neutropenia

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Durata Therapeutics completes dalbavancin Phase 3 trials on ABSSSI

Arsanis to develop monoclonal antibody therapeutics against nosocomial infections

Strep throat should be treated with penicillin or amoxicillin: IDSA guidelines

Methodist Hospital develops new technology to rapidly detect drug-resistant TB

Recent data from Silence Therapeutics’ Atu111 pre-clinical study on acute lung injury

Scientists characterize the lung squamous cell carcinoma genome

Antibiotic treatment more effective than placebo in patients with mild-to-moderate COPD

Research roundup: Reducing risk in shared savings programs

Enrollment complete in DOUBle Phase 3 clinical trial of AzaSite Plus and DexaSite for blepharitis

Durata completes target enrollment in dalbavancin Phase 3 trials for abSSSI

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

Coconut oil attacks tooth decay

Meijer offers generic Lipitor for free to help families be heart healthy

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News